Disclosed is pharmaceutical solid dosage form comprising an effective amount of metaxalone, at least one inactive powder excipient selected from a group comprising sparingly water-soluble or essentially water-insoluble, natural or synthetic hydrocolloids and polymers, and optionally at least one nonvolatile liquid, prepared by the method comprising the steps of: i. providing an effective amount of metaxalone； ii. providing at least one inactive powder excipient selected from a group comprising natural or synthetic hydrocolloids and polymers； iii. blending the effective amount of metaxalone and the at least one inactive powder excipient； iv. wetting the blend with at least one volatile liquid and optionally at least one non-volatile liquid to form a mix； v. granulating the mix to form a granulation； vi. drying and milling the granulation； vii. mixing with at least one inactive powder excipient； and viii. compressing into a solid dosage form, wherein said dosage form presents improved drug dissolution rate as compared to the metaxalone product of NDA #13-217 (Trade name: Skelaxin). The metaxalone dosage is useful for treating a musculoskeletal condition.
